Related Experiment Video

Updated: Apr 16, 2026

A Protocol for Analyzing Hepatitis C Virus Replication
13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

24.9K

Current status and emerging challenges in the treatment of hepatitis C virus genotypes 4 to 6

Vasilios Papastergiou1, Stylianos Karatapanis1

  • 1Vasilios Papastergiou, Stylianos Karatapanis, Department of Internal Medicine, General Hospital of Rhodes, 85100 Rhodes, Greece.

World Journal of Clinical Cases
|March 20, 2015
PubMed

Insights

Hepatitis C virus (HCV) genotypes 4, 5, and 6 are prevalent in Africa, the Middle East, and Asia. Current treatments show variable response rates, with newer direct-acting antivirals (DAAs) offering future promise.

Area of Science:

  • Hepatology
  • Virology
  • Infectious Diseases

Background:

  • Hepatitis C virus (HCV) genotypes 4, 5, and 6 are geographically concentrated in Africa, the Middle East, and Asia.
  • These genotypes have been less extensively studied compared to others, particularly regarding epidemiology and disease progression.
  • Limited data exists on optimal therapeutic strategies for these specific HCV genotypes.

Purpose of the Study:

  • To review the current understanding of Hepatitis C virus (HCV) genotypes 4, 5, and 6.
  • To evaluate the efficacy of existing and emerging treatments for these genotypes.
  • To highlight the challenges and future directions in managing HCV 4-6 infections, especially in resource-limited settings.

Main Methods:

  • Literature review of epidemiological data, natural history, and therapeutic outcomes for HCV genotypes 4, 5, and 6.
  • Analysis of response rates for peginterferon/ribavirin combination therapy.
  • Assessment of recent recommendations for direct-acting antiviral (DAA) regimens.

Main Results:

  • Peginterferon/ribavirin treatment shows variable response rates: 40%-69% for HCV 4, 55%-60% for HCV 5, and 60%-90% for HCV 6.
  • Response-guided therapy is recommended for HCV 4 and preliminarily for HCV 6, but not yet for HCV 5.
  • Pan-genotypic DAAs (simeprevir, sofosbuvir, daclatasvir) are now recommended in triple regimens with peginterferon/ribavirin for HCV 4-6.

Conclusions:

  • Direct-acting antiviral (DAA)-based interferon-free therapies are expected to significantly improve HCV treatment outcomes.
  • Continued efforts to optimize peginterferon/ribavirin treatment are crucial due to the accessibility and cost of DAAs in resource-limited regions where HCV 4-6 are prevalent.
  • Further research is needed to support individualized therapy for HCV 5 and to ensure equitable access to advanced treatments globally.

Keywords:
Direct-acting antiviralsGenotype 4Genotype 5Genotype 6Hepatitis C virusPegylated interferonRibavirin

More Related Videos

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks10:28

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

Published on: June 26, 2020

10.4K
A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

2.8K

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver.
63
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
36
Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
50.8K
Viruses with RNA Genomes01:29

Viruses with RNA Genomes

RNA viruses are categorized into positive-strand, negative-strand, or double-stranded groups based on their genomic structure and replication mechanisms. This classification dictates how they exploit host cellular machinery for protein synthesis and replication. Some RNA viruses also utilize reverse transcription as part of their life cycle, further diversifying their replication strategies.Positive-Strand RNA VirusesPositive-strand RNA viruses have genomes that function directly as messenger...
1.4K
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
78